Janumet^™: a combination product suitable for use in patients with Type 2 diabetes

Bibliography

• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US. Adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Cefalu WT. Evaluation of alternative strategies for optimizing glycemia; progress to date. Am J Med 2002;113(6A):S23-35
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287(2):E199-206
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47(11):1663-70
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc) 2007;43(10):681-9
   PubMed Web of Science ®Google Scholar
• Deacon CF, Ahren B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004;13(9):1091-102
   PubMed Web of Science ®Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38(4):665-73
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273(5 Pt 1):E981-8
   PubMed Web of Science ®Google Scholar
• Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86(9):4382-9
   PubMed Web of Science ®Google Scholar
• Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006;40(7-8):1336-43
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48(4):612-5. Epub 2005 Mar 10
   PubMed Web of Science ®Google Scholar
• Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms [review]. Drugs 1999;58(1 Suppl):31-9; discussion 75-82
   PubMedGoogle Scholar
• Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24(3):489-94
   PubMed Web of Science ®Google Scholar
• Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002;298(5):779-84
   PubMed Web of Science ®Google Scholar
• Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61(1):171-80. Epub 2006 Dec 5
   PubMed Web of Science ®Google Scholar
• Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79(2):291-8
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29(12):2632-7
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, et al. Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49(11):2564-71
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007. [Epub ahead of print]
   PubMedGoogle Scholar
• Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9(5):733-45. Epub 2007 Jun 26
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, et al. Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87. Epub 2007 May 7
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, et al. Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29(12):2638-43
   PubMed Web of Science ®Google Scholar
• Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9(2):186-93
   PubMed Web of Science ®Google Scholar
• Raz I, Chen Y, Wu M, et al. Efficacy and Safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24(2):537-50
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008. [Epub ahead of print] (doi: 10.1111/j.1463-1326.2007.00839.x)
   Google Scholar
• Kim D, Wang L, Beconi M, et al. (2R)4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Clin Endocrinol Metab 2006;91(11):4612-9
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54(10):2988-94
   PubMed Web of Science ®Google Scholar
• Janumet TM (sitagliptin/metformin HCl) tablets [package insert]. Whitehouse Station, New Jersey: Merck & Co. Inc; 2007
   Google Scholar
• Herman GA, Bergman A, Wagner JA. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia 2006;49(1 Suppl):481
   Google Scholar
• Lyseng Williamson KA. Sitagliptin. Drugs 2007;67(4):587-97
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30(7):1862-4. Epub 2007 Apr 27
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
   PubMed Web of Science ®Google Scholar
• Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the DPP-4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35(4):533-8
   PubMed Web of Science ®Google Scholar
• Stevens C, Bergman AJ, Liu Q, et al. Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV inhibitor [abstract PII-49]. Clin Pharmacol Ther 2006;79(2):P49
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25(12):2991-3026
   PubMed Web of Science ®Google Scholar
• Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycemic agent. Am J Health Syst Pharm 1997;54:893-903
   PubMed Web of Science ®Google Scholar
• Januvia TM. (sitagliptin) Tablets [package insert]. Whitehouse Station, New Jersey: Merck & Co., Inc.; updated October 2007
   Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10(7):545-55. Epub 2008 Jun 1
   PubMed Web of Science ®Google Scholar
• Melikan C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization; a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7
   PubMed Web of Science ®Google Scholar
• Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5(6):424-31
   PubMed Web of Science ®Google Scholar
• Sarafidis PA. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundam Clin Pharmacol 2008;22(3):247-64
   PubMed Web of Science ®Google Scholar